Mainz Biomed BV
NASDAQ:MYNZ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Mainz Biomed BV
Cash Interest Paid
Mainz Biomed BV
Cash Interest Paid Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Interest Paid | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Mainz Biomed BV
NASDAQ:MYNZ
|
Cash Interest Paid
$198.1k
|
CAGR 3-Years
58%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Cash Interest Paid
€11m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
Cash Interest Paid
€2.3m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Cash Interest Paid
€946k
|
CAGR 3-Years
11%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Immunic Inc
NASDAQ:IMUX
|
Cash Interest Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Cash Interest Paid
€14.5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
18%
|
CAGR 10-Years
-8%
|
|
Mainz Biomed BV
Glance View
Mainz Biomed BV operates as a biotechnology company. The company is headquartered in Mainz, Hessen. The company went IPO on 2021-11-04. The firm operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The firm competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
See Also
What is Mainz Biomed BV's Cash Interest Paid?
Cash Interest Paid
198.1k
USD
Based on the financial report for Dec 31, 2024, Mainz Biomed BV's Cash Interest Paid amounts to 198.1k USD.
What is Mainz Biomed BV's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 5Y
4%
Over the last year, the Cash Interest Paid growth was 29%. The average annual Cash Interest Paid growth rates for Mainz Biomed BV have been 58% over the past three years , 4% over the past five years .
